396 related articles for article (PubMed ID: 24297449)
1. Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo.
Zhao Y; Yu D; Wu H; Liu H; Zhou H; Gu R; Zhang R; Zhang S; Wu G
Int J Oncol; 2014 Feb; 44(2):451-8. PubMed ID: 24297449
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo.
Yang B; Yu D; Liu J; Yang K; Wu G; Liu H
Tumour Biol; 2015 Jul; 36(7):5051-61. PubMed ID: 25649979
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
Imre G; Gekeler V; Leja A; Beckers T; Boehm M
Cancer Res; 2006 May; 66(10):5409-18. PubMed ID: 16707469
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
Wu Z; Ma C; Shan Z; Ju Y; Li S; Zhao Q
J BUON; 2013; 18(4):1032-7. PubMed ID: 24344034
[TBL] [Abstract][Full Text] [Related]
6. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
8. Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide.
Chien CW; Yao JH; Chang SY; Lee PC; Lee TC
Toxicol Appl Pharmacol; 2011 Nov; 257(1):59-66. PubMed ID: 21889949
[TBL] [Abstract][Full Text] [Related]
9. Effects of trichostatin A on HIF-1α and VEGF expression in human tongue squamous cell carcinoma cells in vitro.
Kang FW; Que L; Wu M; Wang ZL; Sun J
Oncol Rep; 2012 Jul; 28(1):193-9. PubMed ID: 22552321
[TBL] [Abstract][Full Text] [Related]
10. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
Park KC; Kim SW; Park JH; Song EH; Yang JW; Chung HJ; Jung HJ; Suh JS; Kwon HJ; Choi SH
Cancer Sci; 2011 Feb; 102(2):343-50. PubMed ID: 21159061
[TBL] [Abstract][Full Text] [Related]
11. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of riccardin D on growth of human non-small cell lung cancer: in vitro and in vivo studies.
Xue X; Sun DF; Sun CC; Liu HP; Yue B; Zhao CR; Lou HX; Qu XJ
Lung Cancer; 2012 Jun; 76(3):300-8. PubMed ID: 22261315
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo.
Wei Y; Zhou F; Lin Z; Shi L; Huang A; Liu T; Yu D; Wu G
Anticancer Drugs; 2018 Mar; 29(3):262-270. PubMed ID: 29356692
[TBL] [Abstract][Full Text] [Related]
14. Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin‑induced Src activation in gastric cancer cells.
Zhou C; Ji J; Shi M; Yang L; Yu Y; Liu B; Zhu Z; Zhang J
Mol Med Rep; 2014 Nov; 10(5):2729-35. PubMed ID: 25199623
[TBL] [Abstract][Full Text] [Related]
15. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis.
Huang YC; Huang FI; Mehndiratta S; Lai SC; Liou JP; Yang CR
Oncotarget; 2015 Jul; 6(21):18590-601. PubMed ID: 26087180
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits anti-inflammatory activities through induction of mitochondrial damage and apoptosis in activated lymphocytes.
Shi ZJ; Ouyang DY; Zhu JS; Xu LH; He XH
Int Immunopharmacol; 2012 Apr; 12(4):580-7. PubMed ID: 22369900
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells.
Cheng HT; Hung WC
Oncol Rep; 2013 Mar; 29(3):1238-44. PubMed ID: 23242251
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
[TBL] [Abstract][Full Text] [Related]
19. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line.
Duo J; Ma Y; Wang G; Han X; Zhang C
DNA Cell Biol; 2013 Apr; 32(4):156-64. PubMed ID: 23451817
[TBL] [Abstract][Full Text] [Related]
20. Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
Shi XY; Ding W; Li TQ; Zhang YX; Zhao SC
Med Sci Monit; 2017 Dec; 23():5793-5802. PubMed ID: 29211704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]